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Knowledge about the regulation of cell lineage-spe-
cific expression of extracellular matrix metalloprotein-
ases is limited. In the present work, the murine matrix
metalloproteinase 9 (MMP-9) gene was shown to contain
13 exons, and the 2.8-kilobase pair upstream region was
found to contain several common promoter elements
including a TATA box-like motif, three GC boxes, four
AP-1-like binding sites, an AP-2 site, and three PEA3
consensus sequences that may be important for basic
activity of the gene. In order to identify cell-specific
regulatory elements, constructs containing varying
lengths of the upstream region in front of a LacZ re-
porter gene were made and studied for expression in
transgenic mice generated by microinjection into fertil-
ized oocytes. Analyses of the mice revealed that the pres-
ence of sequences between 22722 and 27745 allowed for
expression in osteoclasts and migrating keratinocytes,
i.e. cells that have been shown to normally express the
enzyme in vivo. The results represent the first in vivo
demonstration of the location of cell-specific control el-
ements in a matrix metalloproteinase gene and show
that element(s) regulating most cell-specific activities of
92-kDa type collagenase are located in the 22722 to
27745 base pair region.
Mammalian extracellular matrix metalloproteinases (MMPs)1
form a family of related enzymes that are capable of degrading
various components of the connective tissue (1–3). These pro-
teases are either secreted or membrane-bound and are pro-
duced as latent enzymes. They have a conserved Zn21 binding
catalytic site and can be inhibited by specific tissue inhibitors
of metalloproteinases (4–7). In vitro studies imply diverse sub-
strates and functions for these enzymes in vivo. Several genet-
ically distinct enzymes have been identified. Based on in vitro
substrate specificities, they are placed in different categories:
interstitial collagenases that degrade fibrillar collagens (8–10);
the stromelysins (11–13) with activity against several noncol-
lagenous proteins and collagens with interrupted triple helices;
matrilysin that degrades fibronectin, laminin, casein, gelatin,
and proteoglycans (2); macrophage metalloelastase, which de-
grades elastin (15, 16); MMP-2 and MMP-9, which cleave type
IV collagen and gelatin (17–21), respectively; and finally a
recently described group of the membrane type of matrix met-
alloproteinases that can activate other metalloproteinases and
also degrade matrix proteins (22–24).
The metalloproteinases are believed to have an important
role in normal turnover of extracellular matrix and in remod-
eling of tissues. Furthermore, they have been shown to be
highly expressed in areas of inflammation and tumor invasion.
However, the specific roles of the various metalloproteinases in
vivo as well as regulation of their genes are still largely unex-
plored. MMPs 2 and 9, which form a distinct subgroup of
MMPs, based on their primary structure and substrate speci-
ficity, have been shown to have high activity against gelatin,
and they also degrade type IV, V, and VII collagens. However,
they do not show high activity against type I collagen, proteo-
glycan, or laminin. Despite the apparently identical substrate
specificity, their temporal and spatial expression in vivo varies
extensively, indicating that the two enzymes are required for
different purposes. This is also emphasized by the different
expression patterns of the two genes (21). Thus, MMP-2 is
primarily expressed in stromal fibroblast-like cells during
mouse development (25), while its expression is insignificant in
the stroma of adult mice. This suggests that MMP-2 has a major
role in the remodeling of the stromal compartment, in addition to
the proposed role in the turnover of basement membrane type IV
collagen. In fact, it is possible that the enzyme mainly functions
as a stromal gelatinase by removing gelatin derived from de-
graded fibrillar collagens. In invasive tumors, intense expres-
sion of MMP-2 is observed in stromal cells adjacent to the
tumor front, not in the tumor cells themselves (26–29).
MMP-9 has a completely different expression pattern. By in
situ hybridization analysis, its expression has been shown to be
almost completely confined to osteoclasts at the site of bone
formation during mouse development (30). This is the only
known example of a highly osteoclast-specific proteinase, which
indicates that the enzyme is important for the turnover of bone
matrix, possibly as a gelatinase required for the removal of
denatured collagen fragments (gelatin) generated by intersti-
tial collagenases. MMP-9 expression has also been localized to
keratinocytes of healing skin wound (31), macrophages (27, 28,
29, 32), and trophoblasts of the implanting embryo (33, 34).
We have previously shown that no cell-specific expression
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and regulation of the MMP-9 gene could be achieved through in
vitro experiments using transiently transfected cells (35).
Therefore, to examine the regulation of the MMP-9 gene and, in
particular, the regulatory mechanisms of its tissue expression,
we have cloned and characterized the mouse gene and studied
its regulation using transgenic mice. In this study, we demon-
strated that the minimum element(s) required for expression in
osteoclasts and migrating keratinocytes reside in the 59-flank-
ing region of the gene between 2.7 and 7.7 kb upstream of the
transcription start site.
EXPERIMENTAL PROCEDURES
Isolation and Characterization of the Mouse MMP-9 Gene—Mouse
genomic libraries cloned in the cosmid pWE15 (Stratagene, catalog no.
95303) and l Fix phage (Stratagene, catalog no. 46309) were screened
using a human MMP-9 cDNA probe (pHG1, Ref. 21) labeled with 32P by
random priming. Hybridization was performed in 53 SSC, 53 Den-
hardt’s solution, and 0.1% SDS overnight at 42 °C, after which the
filters were washed at a final concentration of 0.13 SSC and 0.1% SDS
at 42 °C. The clones were isolated and purified utilizing standard pro-
cedures and mapped using restriction endonucleases.
DNA Sequencing—The nucleotide sequence was determined by the
dideoxynucleotide chain termination procedure (36) using Sequenase or
TAQuence DNA sequencing kits (U.S. Biochemical Corp.) and M13
universal primers or specific oligonucleotide primers. Both strands of
the gene and its promoter were sequenced following subcloning into
pBluescript II SK1/2 (Stratagene).
Primer Extension—Total RNA from 7-day-old mouse skull was iso-
lated by the acid guanidium thiocyanate/phenol chloroform extraction
method (37). Primer extension was performed by hybridizing 20 mg of
total RNA with an antisense nucleotide primer annealing at positions
117–144 in the cDNA (Ref. 30, Fig. 1). The primer was end-labeled by
[g-32P]ATP using T4 polynucleotide kinase (38). The reverse tran-
scription reaction was carried out under standard conditions, and the
primer-extended products were run on a sequencing gel along with
sequencing reactions from the mouse MMP-9 gene using the same
oligonucleotide as in the primer extension assay.
Plasmid Constructs—Promoter-LacZ reporter gene constructs were
created using the pKK2480 vector (kindly provided by Mikkel Rohde,
University of Copenhagen, Denmark), which contains a multiple clon-
ing site immediately upstream of the LacZ gene. Different length seg-
ments of the 59-flanking region as well as the 59-end of the MMP-9 gene
containing the first exon and intron were excised with appropriate
restriction enzymes and used for the construction of MMP-9/LacZ fu-
sion genes.
Generation and Analysis of Transgenic Mice—Transgenic animals
harboring promoter-reporter gene constructs were generated by injec-
tion of the linearized LacZ fusion constructs into pronuclei of fertilized
mouse oocytes C57BL/6 3 DBA/2 F1 (39). Microinjected eggs (15–20)
were then transferred into the oviduct of pseudopregnant NMRI mice,
and the mice were allowed to develop to term. At 3 weeks of age, tail
DNA was isolated (40), and transgenic animals were identified by
polymerase chain reaction analysis using two internal primers of the
LacZ gene (41). Mouse embryos from positive mice were recovered at
different time points and fixed for 2 h or overnight at 4 °C in 2%
paraformaldehyde, 0.2% glutaraldehyde in PBS. They were stained
with 5-bromo-4-chloro-3-indolyl-b-galactopyronoside (X-gal) as described
by Behringer et al. (42).
Histologic and Immunohistochemical Analyses—X-gal-stained
mouse embryos and other tissues were rinsed several times in PBS,
dehydrated, and embedded in paraffin. Sections of 5–8 mm were stained
either by hematoxylin and eosin (43) or with safranin. Sections were
stained for 2–5 min in 0.2% safranin, 1% acetic acid, differentiated for
1–5 s in 95% ethanol, 2–5 s in absolute ethanol, and mounted from
xylene.
Immunohistochemical staining of paraffin sections (5–10 mm) from
skin wounds was carried out by using either the ABComplex horserad-
ish peroxidase kit (DAKO) or the TSA kit (NEN Life Science Products).
Deparaffinized sections were treated 5 min. with 0.4% pepsin in 0.01 M
HCl at 37 °C. Endogenous peroxidase activity was quenched by incu-
bation for 20 min in 3% H2O2, and sections were then incubated with
the antiserum raised against cytokeratin (rabbit anti-cytokeratin (Pan),
Zymed Laboratories Inc.) for 1.5 h at room temperature. or MMP-9
(rabbit polyclonal antibody kindly provided by P. Carmeliet) overnight
at room temperature. For the anti-cytokeratin immunostaining, the
sections were washed in PBS, and subsequently, biotinylated Swine
anti-rabbit IgG (Boehringer Mannheim) (1:400 dilution) was applied for
30 min at room temperature. After phosphate-buffered saline washes, a
20-min incubation with ABComplex/horseradish peroxidase was car-
ried out (DAKO Code K355). Peroxidase activity was revealed by incu-
bation with the chromogen substrate 3,3-diaminobenzidine tetrahydro-
chloride. Sections were counterstained with hematoxylin and eosin. For
the MMP-9 immunostaining, peroxidase swine anti-rabbit IgG (DAKO)
was applied and followed by tyramide signal amplification (TSA kit;
NEN Life Science Products). AEC chromogen substrate (DAKO) was
used to detect peroxidase activity. Sections were counterstained with
hematoxylin.
In Situ Hybridization—A mouse MMP-9 cDNA fragment of 324 bp
containing SmaI and EcoRI restriction sites from the M92KD-2 cDNA
clone (bases 1915–2239) (30) was subcloned into pSP64 ans pSP65
plasmid vectors (Promega). The pSP64 (sense) and pSP65 (antisense)
plasmids vectors were linearized with EcoRI and BamHI restriction
enzymes, respectively, and the 35S-uridine 59-triphosphate (1000 mCi/
nmol, Amersham Pharmacia Biotech) labeled RNA probes were tran-
scribed using a transcription kit (Promega). The labeled probes were
precipitated with ethanol, dissolved in hybridization buffer, and used at
50,000–60,000 cpm/ml. The in situ hybridization was carried out ac-
cording to Wilkinson and Green (44). Prior to hybridization the mouse
embryos were stained with X-gal, embedded in paraffin, and sectioned.
The specimens were pretreated as described before (45) and hybridized
with the probe at 5O °C for 16 h. After washing under high stringency
conditions, the sections were dried and dipped in an autoradiographic
emulsion (nitro blue tetrazolium-2; Eastman Kodak Co.), exposed for 14
days at 4 °C. After development of the sections, they were stained with
hematoxylin and mounted.
RESULTS
Structure of the Gene and 59-Flanking Region—Screening of
the genomic libraries yielded several clones, one of which (cos-
mid MGC-1 (about 34 kilobases)), contained the entire 7.7-
kilobase gene (Fig. 1), as well as 3 and 23 kilobases of the 59-
and 39-end flanking regions, respectively. Another l phage
clone CM-1 contained about 11,000 bp of the 59-flanking region.
Sequencing of exons revealed that the murine gene contains 13
exons, which correspond in size to those of the human gene
(Fig. 1, Table I). The only significant differences are exons 9
and 13 which, respectively, contain 54 and 15 base pairs more
than in the human gene. Furthermore, introns 1, 2, 3, and 12 in
the mouse gene are about half the size of corresponding human
introns (21).
The initiation site for transcription as determined by primer
extension revealed a double start site located 19 and 20 bp
upstream of the translated sequence (Fig. 2). Sequencing of
about 2800 base pairs of the 59-flanking region revealed several
common promoter elements (Fig. 1). There is a TATA box-like
motif TTAAA at positions 230 to 225 but no CCAAT box.
There are three GC boxes that may serve as binding sites for
the transcription factor Sp1 (46) (located at positions 262 to
257, 2451 to 2446, and 2598 to 2589). Four AP-1-like binding
sites were also identified (250 to 244, 288 to 280, 2472 to
2465, and 21080 to 21072). Two of those correspond to similar
sequences in the human gene, but sites corresponding to the
first one (250 to 244) and the most upstream one have not
been reported in the human gene. Several conserved sequence
elements with similarity to the polyoma virus enhancer A-bind-
ing protein-3 sites (47) were found in the 59-flanking sequence
(2365 to 2360, 2479 to 2474, 2658 to 2653, and 2901 to
2896), as well as in the first intron (Fig. 1). One consensus
sequence (59-CCCCAGGC-39) for AP-2 (2590 to 2483), several
microsatellite segments of alternating CA residues, as well as
one NF-kB motif (2527 to 2519) were also present. A putative
tumor growth factor-b1-inhibitory element found in the human
gene was absent in the murine promoter. During the course of
this work, characterizations of the MMP-9 gene from mouse
(48) and rabbit (49) were published.
Generation of Transgenic Mice—In order to explore the reg-
ulatory mechanisms of the MMP-9 gene, we generated trans-
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genic mice by microinjection of different promoter-reporter
gene constructs into fertilized oocytes. A total of six constructs
containing different portions of the 59-end of the gene and the
b-galactosidase gene as a reporter were made (Fig. 3). Three
constructs, 645-LacZ, 2700-LacZ, and 7700-LacZ, contained
0.65, 2.7, and 7.7 kb of the 59-flanking region, and three con-
structs, 645ExIn-LacZ, 2700ExIn-LacZ, and 7700ExIn-LacZ,
contained additionally the first exon and intron of the MMP-9
gene in front of the LacZ gene. The constructs containing exon
1 had a mutation in the ATG initiator codon for translation
(ATG 3 ATC) to allow translation of the transcript to start
from the ATG methionine initiator codon in the LacZ gene.
FIG. 1. Structure of the mouse MMP-9 gene and sequence of the 5*-end. Top, the entire gene and flanking regions were contained in the
MGC-1 cosmid clone, which reached 23 kilobases downstream from the last exon. The CM-1 l clone further provided about 11 kilobases of the
59-flanking region. The restriction map was obtained using NotI (N), XhoI (X), BamHI (B), EcoRI (E), and HindIII (H). Middle, the exons of the
gene are depicted by boxes, numbered from the 59-end, and the introns and flanking sequences are shown by a solid line. Scale in kilobases is shown.
Bottom, nucleotide sequence of the 59-end flanking region. The bent arrow indicates the transcription initiation site as determined by primer
extension. The numbering of nucleotides starts at the transcription initiation site. The TATA motif, GC boxes, AP-1-like, AP2, polyoma virus
enhancer A-binding protein-3, and NF-kB binding consensus sequences are boxed. Alternating CA-rich sequences are underlined.
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Intron 1 was included in some of the construct, since it has been
shown to contain enhancer elements in other genes such as
that for the a1 chain of type I collagen (50). Three to eight lines
of mice were generated with each construct to ensure that the
expression pattern obtained with each construct was repeat-
able. Polymerase chain reaction and Southern analyses were
carried out to establish integration of the inserts into the ge-
nome, and histochemical analyses with X-gal provided evidence
about cell-specific expression patterns of the transgene.
Expression of MMP-9 Promoter/LacZ Reporter Constructs in
Transgenic Mice—Transgenic mice were first generated with
constructs containing the minimum promoter, 645-LacZ, and a
longer one, 2700-LacZ, containing 2.7 kb of the upstream re-
gion. However, mice and mouse embryos made with these
constructs did not yield any expression of the LacZ gene in cells
that normally express MMP-9 in transgenic embryos or adult
tissues. Ectopic expression could be observed in some lines with
both constructs, but its pattern was neither uniform nor re-
peatable in four founder lines analyzed (data not shown). The
addition of the 59-end of the MMP-9 gene, including intron 1, to
constructs 645-LacZ and 2700-LacZ (i.e. the 59-untranslated
region and the first exon and intron) did not alter the expres-
sion pattern. Consequently, it could be concluded that the first
intron does not contain cis-acting elements conferring tissue-
specific expression of the endogenous MMP-9 gene.
Due to the lack of expression with the constructs described
above, we made another one, 7700-LacZ, containing 7.7 kb of
the upstream sequence and generated transgenic mice. In con-
trast, to the shorter constructs, mouse embryos harboring
7700-LacZ revealed expression of the LacZ gene in bones of
14.5–16.5-day-old embryos. For example, at embryonic day
15.5, distinct expression could be observed in the scapula, long
bones of fore and hind limbs, ribs, and the lower jaw (Fig. 4).
Additionally, expression was observed in hair follicles in differ-
ent mouse lines made with this construct. Construct 7700ExIn-
LacZ, containing additionally the first exon and intron, yielded
similar expression pattern in bones as 7700-LacZ when ana-
lyzed in whole X-gal-stained embryos, with the exception that
no expression was present in hair follicles (Fig. 4).
The 22722 to 27745 Upstream Region of the MMP-9 Gene
Confers Expression to Osteoclasts—Only mice made transgenic
with constructs containing 7.7 kb of the 59-flanking region of
the MMP-9 gene yielded expression of the LacZ gene in bones
as shown in whole embryos in Fig. 4. In order to assess the
expression pattern at the cellular level, we carried out micro-
scopic histochemical analysis, partially combined with in situ
hybridization, to establish if the LacZ expression corresponds
to that of the endogenous gene. In Fig. 5, A and B, staining with
TABLE I
Exon-intron junctions of the mouse gene for MMP-9
Nucleotide sequences at the intron (lowercase letters) and exons (uppercase letters) junctions are shown. The derived amino acid sequence and
corresponding position in the polypeptide are displayed below. Amino acids encoded by split codons are listed twice and partially in parentheses.
Asterisks indicate translation stop codon.
Exon/intron




1 .......... ATG AGT CCC... ....CTG GCA GAG gtagacagat 141 1 19 435
Met Ser Pro Leu Ala Glu
1 47
2 ccatccacag GCA TAC TTG... ....ATC ACA TAC TG gtgagatgtc 230 223
Ala Tyr Leu Ile Thr Tyr Tr(p)
48 124
3 tcacctccag G ATC CAA AAC... ....GGT GTG GCG G gtgagaattc 149 270a
Tr(p) Ile Gln Asn Gly Val Ala Gl(u)
125 174
4 cctcttgcag AG CAC GGA GAC... ....AAA GGC GTC G gtgagatcct 129 106
Gl(u) His Gly Asp Lys Gly Val Va(l)
175 217
5 ctttctacag TG ATC CCC ACT... ....CCT AGT GAG A gtgagtatgc 174 176
(Va)l Ile Pro Thr Pro Ser Glu Ar(g)
218 275
6 gtcaggtcag GA CTC TAC ACA... ....CCT ACC CGA G gtacctctgc 174 350
(Ar)g Lys Tyr Thr Pro Thr Arg Va(l)
276 333
7 gtctctccag TG GAC GCG ACC... ....CCA GAC CAA G gtgagcgggg 177 105
(Va)l Asp Ala Thr Pro Asp Gln Gl(y)
334 392
8 taccttccag CC TAC AGC CTG... ....TAT CTG TAT G gtgaggctgg 156 1150a
(Gl)y Tyr Ser Leu Tyr Leu Tyr Gl(y)
393 444
9 ttgtttttag GT CGT GGC TCT... ....TTC AAG GAC GG gtaagcaggg 334 102
(Gl)y Arg Gly Ser Phe Lys Asp Gl(y)
445 555
10 ttcttctcag T TGG TAC TGG... ....TTC TTC TCT G gttagtttgt 140 270
(Gl)y Trp Tyr Trp Phe Phe Ser (Gl)y
556 602
11 tcttccgcag GA CGT CAA ATG... ....CGT GTC TGG AG gtaagagcga 151 103
(Gl)y Arg Gln Met Arg Val Trp Ar(g)
603 652
12 ccttctgcag A TTC GAC TTG... ....CAG TAC CAA G gtgagggctg 104 1125a
(Ar)g Phe Asp Leu Gln Tyr Gln As(p)
653 687
13 tttcccgtag AC AAA GCC TAT... ....CAG TGC CCT TGA 131 1 943 39-UTRb
(As)p Lys Ala Tyr Glu Cys Pro ***
688 730
a Size determined by polymerase chain reaction with specific oligonucleotides.
b Untranslated region.
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X-gal shows expression of the transgene in single cells located
at the site of endochondral ossification in the diaphysis of long
bones, beneath hypertrophic chondrocytes of the epiphysis.
This result is practically identical to what we have previously
shown for the endogenous gene by in situ hybridization (30). In
that report, we also assigned the endogenous gene expression
specifically to cells that were shown to be osteoclasts by histo-
chemical staining with tartrate-resistant acid phosphatase. In
order to demonstrate that the cells expressing 7700-LacZ were
indeed osteoclasts, we carried out in situ hybridization of X-gal-
stained tissues, and these experiments showed the signals to be
present in cells positive for the blue color produced by b-galac-
tosidase (Fig. 5C). These experiments demonstrated that ex-
pression of the 7700-LacZ construct was confined to osteoclasts
in developing bone. Transgenic mice harboring insert 7700ExIn-
LacZ showed exactly the same expression pattern as construct
7700-LacZ, demonstrating that the upstream segment 22722
to 27745 includes the cis-regulatory element(s) required for
osteoclast expression.
Localization of 7700-LacZ Expression to Migrating Keratino-
cytes—MMP-9 has been shown to be expressed in cultured
keratinocytes (31), but our previous in situ hybridization stud-
ies in developing embryos and adult mice did not reveal expres-
sion of the gene in normally developing epithelia (30). However,
we have shown by in situ hybridization that the MMP-9 gene is
expressed in migrating keratinocytes of healing skin wounds,
indicating a role for the enzyme in the repair process (28). To
examine if any of the MMP-9 promoter-LacZ gene constructs
FIG. 3. Schematic illustration of the
MMP-9 promoter-LacZ reporter gene
constructs. The numbers on the con-
structs are the distance (in base pairs)
from the transcription initiation site (11).
The three lowest constructs (7700ExIn-
LacZ, 2700 ExIn-LacZ, and 645ExIn-
LacZ) contain the first exon (141 bp) and
intron (435 bp) of the MMP-9 gene. The
asterisk in these constructs depicts the
presence of a point mutation introduced
to the ATG codon (ATG mutated to ATC),
so that translation starts from the ATG
codon in the LacZ gene.
FIG. 4. Expression of MMP-9 promot-
er/LacZ constructs in 15.5-day-old
transgenic mouse embryos. Embryos
containing 7700-LacZ yield expression in
the scapula, long bones, fore and hind
limbs, ribs, and the lower jaw. Further-
more, strong expression is present in hair
follicles. Embryos transgenic for con-
struct 7700ExIn-LacZ reveal essentially
the same expression pattern as 7700-
LacZ, except that the expression in hair
follicles is absent.
FIG. 2. Determination of the transcription initiation site. The
mRNA start site was localized by primer extension analysis using
poly(A) RNA from mouse skull as described under “Experimental Pro-
cedures.” Lanes 1–4, results from a co-run of the sequencing reactions
of cloned genomic DNA with guanidine (G), adenosine (A), thymidine
(T), and cytosine (C) indicated at the top. The transcription start site is
shown in lane 5.
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are expressed in epithelial cells, we analyzed tissues from mice
made transgenic with the different constructs for expression of
b-galactosidase. In general, we did not observe expression of
the transgene in epithelia of organs such as skin, lung, or
gastrointestinal tract with any of the six constructs made in
this study.
We then analyzed if keratinocytes of healing skin wounds
expressed the constructs. Incision wounds of about 1 cm were
introduced into the dorsal skin and sutured with a couple of
stitches to bring the wound edges together. When pieces of
whole recovering wounds were stained with X-gal 1–7 days
later, expression of LacZ could be followed in mice harboring
constructs containing 7.7 kb of the 59-flanking region of the
MMP-9 gene (Fig. 6, A–G). When the surface of a wound was
stained with X-gal, one could macroscopically observe cells
expressing b-galactosidase at the wound edges (Fig. 6A). Stain-
ing of tissue sections from the wounds demonstrated strong
positive reaction in keratinocytes migrating in under the fibrin
clot covering 2-day-old wound (Fig. 6, B and C). Fig. 6D, show-
ing double staining of sections with X-gal and anti-MMP-9
antibodies, demonstrated that most migrating keratinocytes
expressing X-gal also costained with the MMP-9 antibody. Fur-
thermore, scattered cells, presumably macrophages, beneath
the wound contained the protein, and some of them also ex-
pressed the LacZ reporter gene. The fact that all cells and their
immediate surroundings stained with the MMP-9 antibody but
not X-gal may be due to secretion of the MMP-9 enzyme.
Identification of b-galactosidase-expressing cells as keratino-
cytes was carried out by counterstaining with cytokeratin an-
tibodies (Fig. 6, E and F). Keratinocytes resting on the normal
basement membrane adjacent to the wound did not show any
staining reaction. At day 7, the reepithelialization process was
FIG. 5. Expression of 7700ExIn-LacZ in developing bone. In A (43 objective) and B (103 objective) expression of LacZ is present in single
cells located at the site of endochondral ossification in the diaphysis (d) of tibia beneath hypertrophic chondrocytes of the epiphysis (e) shown with
safranin and X-gal stain. C, in situ hybridization and X-gal staining demonstrate that the 7700ExIn-LacZ transgene and endogenous MMP-9 are
coexpressed in most osteoclasts (arrows).
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complete. The new epidermis was thicker, and the presence of
fibrotic tissue was apparent, but expression of b-galactosidase
by keratinocytes had ceased (Fig. 6G). In all founder lines, cells
at wound edges expressed b-galactosidase.
DISCUSSION
It is well established that some of the members of the large
family of MMPs exhibit highly restricted temporal and spatial
expression patterns in vitro, indicating tissue-specific roles for
these enzymes in extracellular matrix turnover. However,
there are currently no reports on the regulatory mechanisms
driving these cell lineage-specific expression patterns. The pres-
ent study provides the gene structure and sequence of the pro-
motor region of mouse MMP-9 as well as evidence that cis-
regulatory element(s) necessary for the most of the cell-specific
expression patterns of MMP-9 reside in a region between 2722
and 7745 base pairs upstream of the transcription initiation site.
The mouse gene was shown to be 7.7 kilobases and to contain
13 exons as previously shown for the human, mouse, and rabbit
genes (21, 48, 49). The present study revealed the presence of
two potential transcription initiation sites at positions 19 and
20 upstream of the ATG translation initiator codon. One of
those sites corresponds to the site mapped for the human gene
(21), but they differ slightly from that reported by Masure et al.
(48). Sequencing of the upstream region revealed high se-
quence conservation between 21 and 2600 bases in the mouse
and human genes. Both genes have a TATA box-like motif,
TTAAA, at about position 230 and lack a CCAAT box. The
mouse gene has three GC boxes and three AP-1-like binding
sites, as opposed to one and two in the human gene, respec-
tively (21). Additionally, the mouse gene has a fourth AP-1-like
motif further upstream. Several CA repeat microsatellite seg-
ments were observed in the 2722-base pair upstream sequence
in the mouse gene, including one located close to the transcrip-
tion initiation site as in the human counterpart. Computational
analysis of the 59-flanking region of the gene revealed several
additional putative binding sites whose functionality and ne-
cessity for MMP-9 gene regulation still remain to be assigned.
However, one or more of those binding sites have been impli-
cated in mediating the effects of a diverse set of agents, which
include tumor necrosis factor a, 12-O-tetradecanoyl-phorbol-
13-acetate (51), v-Src (52), and Ha-Ras (53). While those stud-
ies focused on determining the transcriptional requirements
for MMP-9 induction, they do not provide any information on
regulatory requirements driving cell lineage-specific expres-
FIG. 6. Expression of 7700ExIn-
LacZ in incision skin wounds. A, X-gal
staining of the surface of a 3-day-old
wound reveals positive staining of cells
located at the wound edge. B, in a cross-
section of a 2-day old wound, single cells
migrating over the wound beneath the fi-
brin clot show expression of b-galactosid-
ase. In contrast, keratinocytes resting on
a mature basement membrane on both
sides of the wound do not express the
transgene, shown with hematoxylin-eosin
and X-gal staining. C, amplification of the
boxed area in A. D, double staining of a
2-day-old wound with X-gal and anti-
MMP-9 antibodies. Most of the migrating
keratinocytes exhibit codistribution of X-
gal and MMP-9, while keratinocytes of
the normal epithelium at the edges of the
wound are negative for both. Some cells in
the dermis and their immediate sur-
rounding, presumably macrophages,
show the presence of the MMP-9 protein,
and some of those cells also show reaction
with X-gal. E, immunostaining of a 2-day-
old wound with anti-cytokeratin antibod-
ies of a hematoxylin-eosin and X-gal-
stained tissue demonstrates that cells
expressing 7700ExIn-LacZ are keratino-
cytes. F, amplification of the region boxed
in E. G, 7-day-old wound. Reepithelializa-
tion is complete. The new epithelium over
the fibrotic scar tissue is thicker than the
adjacent normal epithelium. Expression
of 7700ExIn-LacZ has ceased. Hematoxy-
lin-eosin and X-gal stains were used.
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sion of the MMP-9 gene.
The present results from the studies with transgenic mice
demonstrated that the 2722-base pair 59 upstream region does
not confer cell-specific expression in vivo. However, some of the
numerous transcription factor consensus binding motifs con-
tained within this sequence are probably essential for the basic
activity of the MMP-9 promoter, as reported in several studies.
Thus, Yokoo and Kitamura (54) showed in transiently trans-
fected glomerular mesangial cells that AP-1 activation is essen-
tial for the induction of MMP-9 by interleukin-1, which is also
mediated through NF-kB stimulation. Himelstein et al. (55) also
showed in cell transfection studies that motifs of the MMP-9
promoter, such as NF-kB, Sp1, Ets, AP-1, and a retinoblastoma
element participate in transcriptional regulation of the MMP-9
expression. Furthermore, Gum et al. (56) have reported that
mutation of the most downstream AP-1 motif practically abol-
ishes the activity of a MMP-9 promoter-driven CAT reporter.
The experiments with promoter/LacZ reporter gene con-
structs in transgenic mice showed that expression of the
MMP-9 gene in osteoclasts and migrating keratinocytes re-
quires the region between 22722 and 27745. Constructs con-
taining this segment yielded strong expression in osteoclasts
and in migrating keratinocytes of a healing wound. The present
results also demonstrated that the first intron does not contain
an enhancer, as this intron does in several extracellular matrix
genes (50, 57). However, this intron may be important for
restricting ectopic expression, since the 7700-LacZ construct
yielded ectopic expression in epithelial hair follicle cells, while
mice expressing construct 7700ExIn-LacZ only exhibited ex-
pression in cells normally expressing MMP-9.
At the cellular level, both the 7700-LacZ and 7700ExIn-LacZ
constructs were shown to yield highly specific expression in
osteoclasts of developing bone, cells that normally strongly
express MMP-9 (30). Coexpression of b-galactoctisidase with
that of the endogenous gene was verified in situ hybridization
analysis of the same tissue sections with an MMP-9 probe (see
Fig. 5C). In addition to the major expression in osteoclasts,
expression of MMP-9 has been shown to occur in migrating
keratinocytes of a healing wound (27). In this study, both
constructs 7700-LacZ and 7700ExIn-LacZ were expressed in
corresponding keratinocytes of transgenic mice, and we also
showed extensive codistribution of the MMP-9 protein and
LacZ expression by double staining. Therefore, cis-regulatory
element(s) for this expression pattern must also be present in
the sequence between 22722 and 27745. Furthermore, as in
the in vivo situation for the endogenous MMP-9 gene, kerati-
nocytes resting on a normal mature basement membrane did
not express the reporter gene in transgenic mice or contain the
MMP-9 protein, as determined by immunohistochemical stain-
ing. Following complete healing and reepithelialization of the
skin wound at day 7, expression of the reporter gene ceased,
essentially as has been shown for the endogenous gene (27). It
has previously been shown that MMP-9 is expressed in invad-
ing trophoblasts of the implanting embryo (33, 34) as well as by
macrophages infiltrating invasive breast and colon cancers,
while the actual cancer cells do not express the enzyme (29, 58).
We have recently shown that trophoblasts of implanting em-
bryos of mice transgenic for constructs 7700-LacZ and
7700ExIn-LacZ express the reporter gene, and furthermore, in
such transgenic mice macrophages located around invading
exogenous carcinoma cells also express the reporter gene. This
suggests that the 22722 to 27745 segment also contains ele-
ment(s) necessary for induction of expression of the gene in
both trophoblasts and macrophages.2
The results of the present study represent an initial step in
identifying the exact mechanisms of cell lineage-specific ex-
pression of an MMP, which has a highly cell-specific expression
pattern and presumably specific function. Further work will be
aimed at narrowing down the region necessary for this expres-
sion and finally the actual nucleotide sequences responsible for
the activities. It will also be particularly interesting to find out
whether a single or separate elements direct expression to
osteoclasts and macrophages that are both derived from mono-
cytes as well as epithelial keratinocytes that appear to express
the MMP-9 gene only during migration.
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